This was a badly conceived, badly implemented trial that was almost certainly going to produce useless results - by ending it Ross gets the ability to hide other mistakes in design, planning and implementation (but not that it was the company under his leadership that decided to go on this goose chase in the first place).
Ross didn't want to chase COVID around the world - then when COVID came to the hospitals he had Ross managed to die of thirst on a fresh water lake.
The board and major shareholders should do a strategic personnel review and Ross should not be CEO at the other side of that.
Ross capacity to recruit aGVHD patients into his trials (or others to do that for him) is something I doubt. Rosses continuance as a CEO should be KPIed against his capacity to either outline a recruitment into GvHD trial plan that is credible and then to meet milestones against his plan or he should get out of the damn road (for any competent alternative any major shareholders or competent board if there are any can find) because he isn't even good enough to sell the residual value in the business. He'd sell it too damn cheap.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)